Results 111 to 120 of about 77,609 (253)

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy

BMC Infectious Diseases
Background Globally, 80 million people are suffering from chronic Hepatitis C virus (HCV) infection. Sofosbuvir ribavirin-based anti-HCV therapy is associated with anemia and other adverse effects.
Sameen Amjed, Hafiz Ghulam Murtaza Saleem, Sajjad Ullah, Shahzad Latif, Shabana, Junaid Jafar, Ahmad Bilal Waqar   +6 more
doaj   +1 more source

The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients [PDF]

, 2023
Eman Hemeda, Howaida El Menshawy, Essam E. Hassan   +2 more
openalex   +1 more source

Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis

Diseases
Background: There is still debate whether ribavirin should be added to direct-acting antivirals (DAAs) for the management of treatment-experienced individuals with non-genotype-1 hepatitis C.
Shahd Hamran, Amani A. Al-Rajhi, Kawthar Jasim, Majed A. Al-Theyab, Mohamed Elahtam, Mooza K. Al-Hail, Wadha Al-Fahaidi, Yaman A. Khamis, Yara Dweidri, Abdel-Naser Elzouki, Tawanda Chivese   +10 more
doaj   +1 more source

Influence of Ribavirin on Prunus Domestica L. Regeneration, Genome Stability and Virus Eradication In Vitro [PDF]

, 2019
Ingrida Mažeikienė, D. Kviklys, J. B. Šikšnianienė, Dainius Zinkus, V. Stanys   +4 more
openalex   +1 more source

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis

Clinical and Experimental Gastroenterology, 2012
Eric Druyts1, Edward J Mills1,2, Jean Nachega3, Christopher O'Regan4, Curtis L Cooper51Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON,
O'Regan C, Nachega J, Mills EJ, Druyts E, Cooper CL   +4 more
doaj  

Ribavirin in respiratory syncytial virus infection. [PDF]

, 1989
Mike Sharland, N.R. Whitehouse, S. Qureshi   +2 more
openalex   +1 more source

Impact of a treatment as prevention strategy on hepatitis C virus transmission and on morbidity in people who inject drugs [PDF]

, 2015
Background: Highly effective direct-acting antiviral (DAA) regimens (90% efficacy) are becoming available for hepatitis C virus (HCV) treatment. This therapeutic revolution leads us to consider possibility of eradicating the virus.
Cousien, Anthony, Deuffic-Burban, Sylvie, Dhersin, Jean-Stéphane, Jauffret-Roustide, Marie, Tran, Viet Chi, Yazdanpanah, Yazdan   +5 more
core   +3 more sources

Preemptive treatment of pediatric bone marrow transplant patients with asymptomatic respiratory syncytial virus infection with aerosolized ribavirin

, 2001
Roberta H. Adams
openalex   +1 more source

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2 [PDF]

, 2017
Jürgen K. Rockstroh, Chloe Orkin, Rolando M. Viani, David Wyles, Anne F. Luetkemeyer, Adriano Lazzarin, Ruth Soto-Malave, Mark Nelson, Sanjay Bhagani, Hartwig Klinker, Giuliano Rizzardini, Pierre‐Marie Girard, Cristina Tural, Nancy S. Shulman, Niloufar Mobashery, Yiran Hu, Linda Fredrick, Edward Tam, Roger Trinh, Edward Gane   +19 more
openalex   +1 more source

10 RIBAVIRIN CONCENTRATION AT WEEK FOUR IS AN INDEPENDEND PREDICTOR FOR SUSTAINED VIROLOGICAL RESPONSE AFTER TREATMENT OF HEPATITIS C GENOTYPE 2/3 (NORDYNAMIC TRIAL)

, 2008
Peer Brehm Christensen, Åsa Alsiö, Mads Rauning Buhl, Martti Färkkilâ, K. Mørch, Per Sangfelt, Martin Lagging, Gunnar Norkrans, C. Pedersen   +8 more
openalex   +1 more source